Role of etanercept in the treatment of tumor necrosis factor receptor-associated periodic syndrome: Personal experience and review of the literature

International Journal of Immunopathology and Pharmacology

Volumn 23, Issue 3, 2010, Pages 701-707

  Cantarini, Luca ^a   Rigante, D ^b   Lucherini, O M ^a   Cimaz, R ^c   Laghi Pasini, F ^a   Baldari, C T ^a   Benucci, M ^d   Simonini, G ^c   Di Sabatino, V ^a   Brizi, M G ^a   Galeazzi, M ^a  

^a UNIVERSITY OF SIENA   (Italy)

^b CATHOLIC UNIVERSITY   (Italy)

^c UNIVERSITY OF FLORENCE   (Italy)

^d SANTA MARIA ANNUNZIATA HOSPITAL   (Italy)

Author keywords

Adalimumab; Etanercept; Infliximab; TNF neutralizing agents; TNFRSF1A gene mutations; Tumor necrosis factor Receptor Associated Periodic Syndrome (TRAPS)

Indexed keywords

ETANERCEPT; TUMOR NECROSIS FACTOR RECEPTOR 1; TUMOR NECROSIS FACTOR RECEPTOR 1A; UNCLASSIFIED DRUG;

FOLLOW UP; GENE MUTATION; HUMAN; PATHOGENESIS; PRIORITY JOURNAL; REVIEW; TUMOR NECROSIS FACTOR RECEPTOR ASSOCIATED PERIODIC SYNDROME;

EID: 78149272003     PISSN: 03946320     EISSN: None     Source Type: Journal    
DOI: 10.1177/039463201002300303     Document Type: Review

References (38)

1. Masters SL, Lobito AA, Chae J, Kastner DL. Recent advances in the molecular pathogenesis of hereditary recurrent fevers. Curr Opin Allergy Clin Immunol 2006; 6:428-33.
2. Dodé C, André M, Bienvenu T, et al. French Hereditary Recurrent Inflammatory Disorder Study Group. The enlarging clinical, genetic, and population spectrum of tumor necrosis factor receptor-associated periodic syndrome. Arthritis Rheum 2002; 46:2181-8.
3. D'Osualdo A, Ferlito F, Prigione I, et al. Neutrophils from patients with TNFRSF1A mutations display resistance to tumor necrosis factor-induced apoptosis: pathogenetic and clinical implications. Arthritis Rheum 2006; 54:998-1008.
4. McDermott MF, Aksentijevich I, Galon J, et al. Germline mutations in the extracellular domains of the 55 kDa TNF receptor, TNFR1, define a family of dominantly inherited autoinflammatory syndromes. Cell 1999; 97:133-44.
5. Hehlgans T, Pfeffer K. The intriguing biology of the tumour necrosis factor/tumour necrosis factor receptor superfamily: players, rules and the games. Immunology 2005; 115:1-20.
6. Banner DW, D'Arcy A, Janes W, et al. Crystal structure of the soluble human 55 kd TNF receptor-human TNF beta complex: implications for TNF receptor activation, Cell 1993; 73:431-45.
7. Chan FK, Chun HJ, Zheng L, Siegel RM, Bui KL, Lenardo MJ. A domain in TNF receptors that mediates ligand-independent receptor assembly and signaling. Science 2000; 288:2351-4.
8. Touitou I, Lesage S, McDermott M, et al. Infevers: An evolving mutation database for auto-inflammatory syndromes. Human Mutation 2004; 24:194-8.
9. Aksentijevich I, Galon J, Soares M, et al. The tumor-necrosis-factor receptor-associated periodic syndrome: new mutations in TNFRSF1A, ancestral origins, genotype-phenotype studies, and evidence for further genetic heterogeneity of periodic fevers. Am J Hum Genet 2001; 69:301-14.
10. Lobito AA, Kimberley FC, Muppidi JR, et al. Abnormal disulfide-linked oligomerization results in ER retention and altered signaling by TNFR1 mutants in TNFR1-associated periodic fever syndrome (TRAPS). Blood 2006; 108:1320-7.
11. Nedjai B, Hitman GA, Yousaf N, et al. Abnormal tumor necrosis factor receptor I cell surface expression and NF-kappaB activation in tumor necrosis factor receptor-associated periodic syndrome. Arthritis Rheum 2008; 58:273-83.
12. Nedjai B, Hitman GA, Quillinan N, et al. Proinflammatory action of the antiinflammatory drug infliximab in tumor necrosis factor receptor-associated periodic syndrome. Arthritis Rheum 2009; 60:619-25.
13. Kimberley FC, Lobito AA, Siegel RM, Screaton GR. Falling into TRAPS-receptor misfolding in the TNF receptor 1-associated periodic fever syndrome. Arthritis Res Ther 2007; 9:217.
14. Nowlan ML, Drewe E, Bulsara H, et al. Systemic cytokine levels and the effects of etanercept in TNF receptor-associated periodic syndrome (TRAPS) involving a C33Y mutation in TNFRSF1A. Rheumatology (Oxford) 2006; 45:31-7.
15. Galon J, Aksentijevich I, McDermott MF, O'Shea JJ, Kastner DL. TNFRSF1A mutations and autoinflammatory syndromes. Curr Opin Immunol 2000; 12:479-86.
16. Hull KM, Drewe E, Aksentijevich I, et al. The TNF receptor-associated periodic syndrome (TRAPS). Emerging concepts of an autoinflammatory disorder. Medicine 2002; 81:349-68.
17. McDermott EM, Smillie DM, Powell RJ. Clinical spectrum of familial Hibernian fever: a 14-year follow-up study of the index case and extended family. Mayo Clin Proc 1997; 72:806-17.
18. Rigante D. Autoinflammatory syndromes behind the scenes of recurrent fevers in children. Med Sci Monit 2009; 15:RA179-87.
19. Nigrovic PA, Sundel RP. Treatment of TRAPS with etanercept: use in pediatrics. Clin Exp Rheumatol 2001; 19:484-5.
20. Arostegui JI, Solis P, Aldea A, et al. Etanercept plus colchicine treatment in a child with tumour necrosis factor receptor-associated periodic syndrome abolishes auto-inflammatory episodes without normalising the subclinical acute phase response. Eur J Pediatr 2005; 164:13-16.
21. Stojanov S, Dejaco C, Lohse P, et al. Clinical and functional characterisation of a novel TNFRSF1A c.605T>A/V173D cleavage site mutation associated with tumour necrosis factor receptor-associated periodic fever syndrome (TRAPS), cardiovascular complications and excellent response to etanercept treatment. Ann Rheum Dis 2008; 67:1292-8.
22. Lamprecht P, Moosig F, Adam-Klages S, et al. Small vessel vasculitis and relapsing panniculitis in tumour necrosis factor receptor associated periodic syndrome (TRAPS). Ann Rheum Dis 2004; 63:1518-20.
23. Drewe E, McDermott EM, Powell PT, Isaacs JD, Powell RJ. Prospective study of anti-tumour necrosis factor receptor superfamily 1B fusion protein, and case study of anti-tumour necrosis factor receptor superfamily 1A fusion protein, in tumour necrosis factor receptor associated periodic syndrome (TRAPS): clinical and laboratory findings in a series of seven patients Rheumatology (Oxford) 2003; 42:235-9.
24. Drewe E, Huggins ML, Morgan AG, Cassidy MJ, Powell RJ. Treatment of renal amyloidosis with etanercept in tumour necrosis factor receptor-associated periodic syndrome. Rheumatology (Oxford) 2004; 43:1405-8.
25. Kallinich T, Briese S, Roesler J, et al. Two familial cases with tumor necrosis factor receptor associated periodic syndrome caused, by a non-cysteine mutation (T50M) in the TNFRSF1A gene associated with severe multiorganic amyloidosis. J Rheumatol 2004; 31:2519-22.
26. Drewe E, Powell RJ, McDermott EM. Comment on: Failure of anti-TNF therapy in TNF Receptor 1-Associated Periodic Syndrome (TRAPS). Rheumatology (Oxford) 2007; 46:1865-6.
27. Scallon B, Cai A, Solowski N, et al. Binding and functional comparison of two types of tumor necrosis factor antagonists. J Pharmacol Exp Ther 2002; 301:418-26.
28. Aganna E, Hammond L, Hawkins PN, et al. Heterogeneity among patients with tumor necrosis factor receptor-associated periodic syndrome phenotypes. Arthritis Rheum 2003; 48:2632-44.
29. Jesus AA, Oliveira JB, Aksentijevich I, et al. TNF receptor-associated periodic syndrome (TRAPS): description of a novel TNFRSF1A mutation and response to etanercept. Eur J Pediatr 2008; 167:1421-5.
30. Simon A, Bodar EJ, van der Hilst JCH, et al. Beneficial response to interleukin I receptor antagonist in TRAPS. Am J Med 2004; 117:208-10.
31. Gattorno M, Pelagatti MA, Meini A, et al. Persistent efficacy of anakinra in patients with tumor necrosis factor receptor-associated periodic syndrome. Arthritis Rheum 2008; 58: 1516-20.
32. Cantarini L, Lucherini OM, Cimaz R, et al. Idiopathic recurrent pericarditis refractory to colchicine treatment can reveal tumor necrosis factor receptor-associated periodic syndrome. Int J Immunol Pharmacol 2009; 22:1051-8.
33. Cantarini L, Lucherini OM, Cimaz R, Baldari CT, Laghi Pasini F, Galeazzi M. Sacroileitis and pericarditis: atypical presentation of tumor necrosis factor receptor-associated periodic syndrome and response to etanercept therapy. Clin Exp Rheumatol 2010; 28:290-91
34. Cantarini L, Lucherini OM, Galeazzi M, et al. Tumour necrosis factor receptor-associated periodic syndrome caused by a rare mutation in the TNFRSF1A gene, and with excellent response to etanercept treatment. Clin Exp Rheumatol 2009; 27:890-1.
35. Gattorno M, Sormani MP, D'Osualdo A, et al. A diagnostic score for molecular analysis of hereditary autoinflammatory syndromes with periodic fever in children. Arthritis Rheum 2008; 58:1823-32.
36. Ravet N, Rouaghe S, Dodé C, et al. Clinical significance of P46L and R92Q substitutions in the tumour necrosis factor superfamily 1A gene. Ann Rheum Dis 2006; 65:1158-62.
37. Trost S, Rosé CD. Myocarditis and sacroiliitis: 2 previously unrecognized manifestations of tumor necrosis factor receptor associated periodic syndrome. J Rheumatol 2005; 32:175-7.
38. Cantarini L, Lucherini OM, Baldari CT, Laghi Pasini F, Galeazzi M. Familial clustering of recurrent pericarditis may disclose tumor necrosis factor receptor-associated periodic syndrome. Clin Exp Rheumatol 2010; 28:405-7.